Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020

Executive Summary

A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels. 

You may also be interested in...

House Wants FDA Action On Non-Pharma Pain Relievers, Breast Density Reports, Pediatric Devices In 2020

The US House Appropriations Committee wants the FDA to foster development of non-pharma and non-opioid pain alternatives, complete mammography breast density reporting regulations, and use an additional $1m Congress would provide to conduct pediatric device trials, among other device initiatives outlined in its 2020 budget bill passed on 4 June.

President Calls For Almost $100M More In Funding For FDA Device Activities In 2020

The current administration would use an additional $98m in congressional budget authority in the 2020 fiscal year for FDA’s medical device efforts to modernize its regulatory approach for technology development, to enable device safety issues to be monitored more closely, and to advance new approaches for regulating digital health technologies and breakthrough devices.

US FDA Device Funding Would Leap By 26% In 2019 Under Trump Budget Proposal

US FDA Device Center program funding would see a $131m increase under the Trump administration's budget proposal, which prioritizes "speeding innovations" in medical devices and other products the agency regulates, and closely examining what regulations need to be revised, updated or eliminated.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts